BIO-Europe EBD Group BIO BIO-Europe
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

BIO-Europe® 2014 Program Overview

The preliminary program for BIO-Europe® 2014 will be available soon

BIO-Europe 2013 program

www.ebdgroup.com/bioeurope/program
Sunday, November 3, 2013
14:00–19:00
Vienna pre-conference tours

Join free tours to explore Vienna's scientific hotspots and meet innovative startups! Tours organized by LISAvienna, the Vienna life science cluster.
Find out more here.

Hosted by:
LISA ViennaLISA Vienna
19:00–21:30
BIO-Europe® Welcome Reception

All BIO-Europe attendees are cordially invited to join us at the Hofburg Vienna for a Welcome Reception.

You will be able to pick up your name badge at the welcome reception.

Cruise Center Altona© WienTourismus/Lois Lammerhuber

Hofburg Vienna
"Grosser Redoutensaal"
Entrance on Josefsplatz 1
1010 Vienna | (map)

Over a period of 700 years, Austria's rulers enlarged the Hofburg Palace to make it a fitting imperial residence. Grosser Redoutensaal, Maria Theresa's elegant ballroom, was extensively refurbished and modernized in 1992. As both a setting for Mozart operas and a location for modern diplomatic summits, here history and the present day go hand in hand.

Sponsored by:

LISA Vienna LISA Vienna

Venue made available by:

BMWJF BMWJF

Monday, November 4, 2013
07:45
Level 0, Foyer A
07:45
Level 0, Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
Collaborative approaches to translational research: Bridging the gap from target to lead

Monday, 09:00–10:30
Level 1, Schubert 1

Despite efforts by academic institutions and industry to work together, the gap from academic discovery to commercial drug development still exists. Meanwhile pharma is realizing that while it is hard to change the shorter term challenges of dried up late stage pipelines, they need to come up with ways to affect the long term outlook for medical innovation. New initiatives have evolved that can advance drug discovery projects along the value chain from idea to drug candidate with proof-of-concept. These include pharma-driven innovation centers, incubators and consortia. Will these models result in better leads for drug development? What impact will they have on the life sciences ecosystem, including the pharma-biotech and biotech-VC relationships?

Moderator:
Matthias Kromeyer – Board Member, MIG

Panelists:
  • Keith Blundy – CEO, Cancer Research Technology Ltd
  • Karimah Es Sabar – President and CEO, The Centre for Drug Research and Development (CDRD)
  • Werner Lanthaler – CEO, Evotec
  • Peter Nussbaumer – Managing Director, Lead Discovery Center
  • Patrick Verheyen – Head, Johnson & Johnson Innovation Center, London
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Personalized medicine in oncology: Turning away from the "one size fits all" therapy?

Monday, 09:00–10:30
Level 0, Stolz 1

Advanced diagnostic tests are making it possible for a patient to get the therapy that fits his genetic composition and his disease. Such advanced personalized medicine raises the hope of an efficient and—on a long-term basis—less cost-intensive therapy with minimal side effects. One of the most notable areas for personalized medicine is for the treatment of cancer. First significant successes demonstrate the importance of personalized medicine in the field of oncology. The understanding of the impact of a medication to a genetic composition as well as the classification of patient groups allow customized treatments. During this workshop practitioners of the pharmaceutical industry will discuss current topics regarding the development, regulatory measures and reimbursement issues within the personalized medicine in oncology.

Moderator:
Peter Homberg – Partner, Dentons

Panelists:
  • Stefan Frings – Global Head of Oncology and Immuno-oncology, Roche Partnering
  • Michael L. Meyers – VP, Oncology Scientific Innovation Lead, Janssen Pharmaceutical Companies of Johnson & Johnson, London Innovation Centre
  • Ronald A. Pepin – Senior VP and Chief Business Officer, Celldex Therapeutics
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Licensing issues and strategic alliance management: How do they work together?

Monday, 09:00–10:30
Level 0, Stolz 2

Pharma companies have realized that the deal is just the beginning of a partnership, and put in place alliance management teams to start working with partners once the ink on the contract has dried. Alliance management if understood by the licensee can be invaluable in managing the deal, the resulting relationship and when necessary, the unwinding of the alliance. This session will discuss how to set up alliance management correctly in the deal documents to identify the key licensing terms related to the deal, to manage the partnership throughout the life of the deal, and to serve as an effective tool for both parties. Panelists will give real life examples of how they manage their alliances "in sickness and in health."

Moderator:
Diane J. Romza-Kutz – Partner, Husch Blackwell LLP

Panelists:
  • Nick Dunscombe – Head of Alliance and Integration Management, AstraZeneca
  • Frank Grams – VP, Head R&D Alliance Management and Transactions, Sanofi
  • Christian Pangratz – Chief Business Officer, Activaero
  • Jason Reid – VP, Investment Banking, Halcyon Cabot Partners
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Is nano becoming the next sweet spot for drug development?

Monday, 09:00–10:30
Level 1, Schubert 5

Drug development licensing activities are often focused on well-established compound classes like small molecules, antibodies, RNA, etc. Over the past decade nanomaterials have found their way to the market, mainly as drug-delivery systems that modify the properties of active compounds (e.g., nano-formulations of chemotherapeutics like Abraxane). Now, companies are starting to use nanomaterials as the active principle for treating diseases, and those nano-therapeutics are commencing clinical development. Through deals with Cytimmune and Bind Biosciences, AstraZeneca and Amgen have recently ventured into nano-therapeutics. What were the reasons for entering into this field now? The panelists will discuss whether nano-therapeutics may become the next compound class. Is pharma ready to add this class into their pipelines based on today's capabilities and infrastructure?

Moderator:
Laurent Levy – CEO, Nanobiotix

Panelists:
  • Detlev Biniszkiewicz – VP and Head of Strategy for Oncology, Innovative Medicines, AstraZeneca
  • Christopher Guiffre – Senior VP and Chief Business Officer, Cerulean Pharma
  • Patrick Tricoli – Global R&D, External Innovation, Scouting and Partnering International, Sanofi
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
New challenges and models in biopharmaceutical manufacturing

Monday, 09:00–10:30
Level 1, Schubert 4

More and more, well-organized CMOs can offer biotechs process development of biopharmaceuticals and manufacturing of material for their clinical trials. However there are new challenges on the horizon for both CMOs and their customers. What influence will these challenges have on the development of new biologics? How much knowledge and risk awareness do biotech customers actually need in order to partner with a CMO for a cost-efficient, high-quality manufacturing process?

Moderator:
Klaus Binder – CEO, Binder Associates GmbH

Panelists:
  • Johannes Clemens – Key Account Manager, Vetter Pharma International
  • John McGuire – Director, New Business Development, DSM Biologics
  • Folker Ruchatz – Senior VP, Biopharmaceuticals Contract Manufacturing Business, Boehringer Ingelheim
  • Klaus B. Schoepe – VP, Project Management, Rentschler Biotechnologie
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:45–10:30
Press conference: aws LISA
From bench to market: Tech transfer strategies in Austria

Monday, 09:45–10:30
Exhibition Hall, Booth 46
 

Moderator:
Johannes Sarx – Managing Director, LISAvienna

Panelists:
  • Michael Losch – Director General, Austrian Federal Ministry of Economy, Family and Youth
  • Edeltraud Stiftinger – Managing Director, austria wirtschaftsservice
  • Peter Halwachs – Managing Director, LISAvienna
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–11:15
Welcome and Opening Remarks

Monday, 10:45–11:15
Level 0, Strauss

Speakers:
  • Florian Schoenhammer – Group Managing Director, EBD Group
  • Michael Losch – Director General, Austrian Federal Ministry of Economy, Family and Youth
  • Renate Brauner – Deputy Mayor, City of Vienna
  • David Thomas – Director, Industry Research and Analysis, Biotechnology Industry Organization (BIO)
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:15–11:30
Keynote Address
The Onyx story: Creating a leading oncology company

Monday, 11:15–11:30
Level 0, Strauss

Speaker:
  • Tony Coles – Former Chairman and CEO, Onyx Pharmaceuticals, Inc.
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:30–12:30
Opening Plenary Session
How can R&D strategy influence patient outcomes?

Monday, 11:15–12:30
Level 0, Strauss

Moderator:
Hubert Birner – Managing Partner, TVM Life Science Management Inc.

Panelists:
  • Tony Coles – Former Chairman and CEO, Onyx Pharmaceuticals, Inc.
  • M. Johnston Erwin – VP of Strategy and Operations, Global External R&D, Eli Lilly and Company
  • Susan Jane Herbert – Executive VP, Global Business Development and Strategy, Merck Serono, a division of Merck KGaA
  • Maya Said – VP, Head of Strategy, Science Policy and External Innovation, Global R&D, Sanofi
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–13:30
Level 0, Exhibit Hall, Foyer Strauss
Level 1, Restaurants
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development Track
Building the drug pipeline of tomorrow: Capturing the potential of the academic research enterprise

Monday, 13:30–14:30
Level 0, Stolz 2

Realignment of research priorities by industry has increased the interest in acquisition of new drug assets. This may be effective as a short-term strategy, but reduced financial support for early stage technologies and academic research is disrupting the development of those technologies that should be partnerable assets in the future. In order to preserve a robust pipeline it is essential to nurture and sustain the potential for academic research, but administrative, communication, and cultural obstacles limit the ability of industry and academic institutions to effectively work together. In this session, a panel of academics and industry will discuss the challenges we face in commercializing nascent technologies, including novel strategies for evaluating, supporting, and/or in-licensing early technologies, how to navigate the technology transfer, IP, and conflict of interest policies of academic institutions, how to overcome common misunderstandings between academics and industry, and how we can work together to better transform the promise of academic research into a robust drug pipeline.

Moderator:
Susan Schaeffer – Editor, BioCentury

Panelists:
  • Scott K. Dessain – CSO, VP, Immunome, Inc.
  • Tomas Landh – Director, Strategy and Innovation Sourcing, Diabetes Research Unit, Novo Nordisk
  • Suzanne Mandala – Executive Director, External Scientific Affairs, MSD
  • Michèle Ollier – Partner, Index Ventures
  • Toby Richardson – Senior Business Development Manager, The Institute of Cancer Research
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Public funding in drug development: Analyzing the dose-effect relationship

Monday, 14:45–15:45
Level 0, Stolz 2

Government funding has become an important source of finance in the biotech industry. Many countries have stepped up their efforts to create new funding models. But what role should government play? Are government agencies equipped to determine which drug candidates and technologies are most likely to be the next medical breakthrough? Do their timelines match up with the timelines of the industry? Can they be as nimble as traditional venture players? At which stages is public funding most necessary and effective, and what are useful funding instruments?

Moderator:
Johannes Sarx – Managing Director, LISAvienna

Panelists:
  • Michael Brandkamp – Managing Director, High-Tech Gründerfonds Management GmbH
  • Ralf Emmerich – Investment Manager, European Investment Fund
  • Regina Hodits – General Partner, Wellington Partners
  • Peter Schintlmeister – Senior Expert, Life Sciences, Federal Ministry of Economy, Family and Youth, Austria
  • Joe Wiley – Principal, Sofinnova Ventures
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
How to position your asset for the optimal deal

Monday, 16:00–17:00
Level 0, Stolz 2

This session provides an overview of key success factors for enhancing your dealmaking success with pharma.

  • At what project stage does biotech need a target product profile and a vision and rationale for the USPs of its product candidate?
  • To what extent can biotech afford shortcuts and gaps in development? We outline the importance of a development plan up to launch for the major regions, and of knowing (and adhering to) big pharma development standards.
  • How crucial is the need for a Health Economic understanding in early development, including the standard of care, associated costs at the time of market entry, the competitive situation at launch, pricing and reimbursement assessment? Should you do it yourself or leave it to the big pharma partner?
  • How important is the market potential in developing countries and what is the impact on IP strategy?
  • What is the best tactic? There are arguments for both creating visibility and contacts in the scientific and pharma community early on, or maintaining a low profile up to the availability of data at a certain development stage.
In this session both pharma and leading consulting firms come together to help you prepare for the deal.

Moderator:
Irina Staatz-Granzer – Owner, Staatz Business Development & Strategy

Panelists:
  • Iain Dukes – Senior VP, Worldwide Licensing and External Scientific Affairs, MSD
  • James O'Mara – VP, Corporate Development, Ironwood Pharmaceuticals
  • Terence G. Porter – VP, Search and Evaluation, Global Business Development, Takeda
  • Charles Wilson – VP, Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research, Inc.
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Major deal transactions

Monday, 17:15–18:15
Level 0, Stolz 2

The panelists in this session examine some of the significant deals of the last 12 months, including transactions they have been involved in, and what these deals reveal about pharma's priorities, strategy and the options available to drug development companies in need of a corporate partner. Join dealmakers from these major companies for a strategic look inside the deal.

Moderator:
Raphael Wisniewski – Partner, Edmond de Rothschild Investment Partners

Panelists:
  • Charlie Alexander – Senior Director, Business Development, Shire
  • James S.J. Manuso – Chairman and CEO, Astex Pharmaceuticals
  • Onno van de Stolpe – CEO, Galapagos
  • Eric Victory – VP, Partnering and Strategy, MedImmune
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Spotlight Track
The right deal at the right time: How are sell-side dealmakers getting it right, or wrong, in today's environment?

Monday, 13:30–14:30
Level 1, Schubert 1

During this session we will take a look at the sell-side of the dealmaking table. We will take the pulse of senior decision makers from biotech to discuss what makes certain transactions more successful than others. Several executives from clinical-stage biotech companies will give a firsthand account of their strategies, challenges faced and outcomes of the partnering experience.

Moderator:
Ruediger Herrmann – Partner, WilmerHale

Panelists:
  • Steve Bryant – VP and Head of Business Development, Genmab
  • Rainer Kramer – CBO, immatics biotechnologies GmbH
  • Walter Schmidt – CEO, AFFiRiS AG
  • Thomas Taapken – CEO, Epigenomics
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
What is the role of large pharma in developing advanced therapy medicinal products—are they essential or not?

Monday, 14:45–15:45
Level 1, Schubert 1

No doubt there are huge market opportunities for companies that can successfully develop and gain approval for regenerative medicine and cell-based therapies with the potential to alter the course of diseases. The road to commercial success for these opportunities is fraught with obstacles, many of which require resources well beyond the means of most regenerative medicine companies. With venture very reluctant to play in this space, can big pharma help fill the funding void? Can companies get beyond clinical POC without a pharma partner? What are the alternatives? Are there other non-traditional partners that could step in and perhaps even help with developing the industrial and commercial infrastructure to support a product launch? This panel will discuss the opportunities for advanced therapies in the larger disease populations where expenses will be greater and timelines longer.

Moderator:
Robert A. Preti – President and Chief Scientific Officer, Progenitor Cell Therapy

Panelists:
  • Claudio Bordignon – Chairman and CEO, MolMed S.p.A.
  • Douglas Doerfler – President and CEO, MaxCyte, Inc.
  • Philippe Lopes-Fernandes – Senior VP and Head, Global Licensing and Business Development, Merck Serono
  • Peter Nolan – Executive Director, Senior VP Commercial Development, Oxford Biomedica
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Financing the future of drug development

Monday, 16:00–17:00
Level 1, Schubert 1

The IPO window is still open, biotech is "hot," but does that mean that more funding is actually available for early stage investments? Or is there just new capital available for a few more mature companies that are able to get through the window before it shuts? In recent years, unconventional sources to fund innovation have sprung up and new financing models are evolving. What vehicles are being used to get drugs through proof of concept? Among the different trends including crowd funding, early stage academic partnerships and CRO collaboration models, which are actually working? This panel explores those and other avenues as they aim to answer the question on everyone's mind—where is the money right now and where is it heading?

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Panelists:
  • Elona Baum – General Counsel and VP, Business Development, CIRM
  • David Donabedian – VP, Head of Venture Investing and Early Stage Collaborations, AbbVie
  • Michèle Ollier – Partner, Index Ventures
  • Barbara Yanni – VP and Chief Licensing Officer, MSD
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
Reimbursement in the Big 6 emerging markets: Implications for market growth and business development

Monday, 17:15–18:15
Level 1, Schubert 1

Healthcare systems in the "Big 6" emerging markets (China, India, Brazil, Russia, Mexico and Turkey) are evolving rapidly, with resultant changes in the way drugs are procured and paid for. What have been largely "out of pocket" systems, with the majority of innovative drugs going to high-income individuals, are becoming state-reimbursed systems. This will have large implications for uptake of new medicines, as well as for access. Several of these markets are already considering the development of heath technology assessment regimes, for example. This panel will provide an overview of these developments, and explore the impact on the expected growth of markets for innovative companies, as well as the prospects for drug and business development there.

Moderator:
Joe Damond – Senior VP, International Affairs, Biotechnology Industry Organization (BIO)

Panelists:
  • Thomas Bols – Managing Director, FTI Consulting
  • Jeffrey P. Kemprecos – Executive Director, Public Policy and Corporate Responsibility, MSD
  • Paul Neureiter – Executive Director for International Governmental Affairs, Amgen
  • Silvia Ondategui-Parra – Partner, Mediterranean Life Sciences Leader and Global Market Access Leader, Ernst & Young
BIO-Europe® 2013
Share this:Email this pageShare this on LinkedInShare this on Twitter
International Seminars
13:30–14:30
Italy

Monday, 13:30–14:30
Level 1, Schubert 5

Welcome
  • H.E. Giorgio Marrapodi – Italian Ambassador to Austria

  • The Italian Biotech Sector
  • Leonardo Vingiani – Director Assobiotec

  • Tuscany: tomorrow's biotech world lab
  • Stefano Giovannelli – Director General Toscana Promozione, Invest in Tuscany

  • Life Sciences in Piemonte – BIO-Europe Spring 2014, March 10–12, Torino
  • Federico Zardi – International Marketing – Project Manager, Piemonte Agency for Investments, Export and Tourism

  • Promoting knowledge-based capital and innovation in international markets
  • Gianpaolo Bruno – Director Strategic Planning, Economic Research, Overseas Offices, Italian Trade Agency, Rome Headquarters
  • BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Belgium - Wallonia

    Monday, 14:45–15:45
    Level 1, Schubert 5

    Case study: Cell therapy in Wallonia, from clinic to market

    We are pleased to invite you to a country session dedicated to cell therapy in Wallonia (Belgium). During this session, we will share with you the promising story of a European region that invests in a technology, cell therapy, which is key to the future of medicine as well as to the economic development of the region. The speakers will also show you how you can integrate your business project in cell therapy in Wallonia.

    Moderator
  • Mr. Frédéric Druck – Communication & International Relations Director, BIOWIN

  • New avenues for a fruitful biomedical cooperation in the heart of Europe
  • Dr. Philippe Janssens de Varebeke – Life Sciences Expert of AWEX (Walloon Agency for Export and Investments)

  • Six years of innovation in the health sector of Wallonia
  • Mr. Frédéric Druck – Communication & International Relations Director, BIOWIN (Health Cluster of Wallonia)

  • Cell therapy in Wallonia, from clinic to market: Case study
  • Mr. Eric Halioua – CEO, Promethera BioSciences

  • You can also meet AWEX, BIOWIN, Promethera BioSciences and seven other companies at the Wallonia/Belgium booth in the exhibition area. AWEX/BIOWIN delegation at BIO-Europe 2013: AWEX, Bioxodes, BIOWIN, Delphi Genetics, Eurogentec, IDDI, ImmuneHealth, Promethera BioSciences, Rommel Consulting Partners, Targetome.

    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    16:00–17:00
    Austria

    Monday, 16:00–17:00
    Level 1, Schubert 5

    Austria: Production and Platform Technologies

    Austria has a wide variety of companies providing production and platform technologies across the whole value chain of production processes. These range from Good Manufacturing Practice (GMP) know-how for setting up pharmaceutical plants to companies producing plasma, special enzymes and other biological substrates and even stem cell products for the repair of bones, cartilage or muscular tissue. Close cooperation among universities, research centers and industry as well as highly trained and experienced experts ensure the highest quality.

    Welcome and Chair
  • Sonja Polan – International Marketing Manager, Life Science Austria

  • Development and manufacturing of liposomal formulations
  • Dietmar Katinger – CEO, Polymun Scientific Immunbiologische Forschung GmbH

  • Maximizing expression levels in yeast: Leveraging novel technologies and exclusive tools for the production of recombinant (human-like glyco)proteins
  • Thomas Purkarthofer – Business Development Manager, VTU Technology GmbH

  • Peptide-Carrier-Fusion Proteins: A novel vaccine platform with broad application potential
  • Rainer Henning – CEO, Biomay AG

  • Zeta Biopharma: Highest competence in biopharmaceutical plant construction
  • Andreas Marchler – Managing Director, Zeta Biopharma GmbH

  • CTAT: A novel enzyme-based technology for conjugating antibodies with drugs (ADCs)
  • Karl Hübler – CEO, EUCODIS Bioscience GmbH

  • BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    17:15–18:15
    Brazil

    Monday, 17:15–18:15
    Level 1, Schubert 5

    The Brazilian biotechnology business scenario

    The aim of this session is to present a picture of the biotechnology sector in Brazil, including cases from two Brazilian companies. The proposal of this presentation is to answer questions such as: In what field of biotechnology are the companies working? Are there special incentives and programs in Brazil? What would be interesting for investment in the biotech field in Brazil? What types of business models work best in Brazil?

    Speaker:
    • Norberto Prestes – Manager of Brasil Biotechnology Project (The National Official Program to promote the internationalization of Brazilian Biotechnology companies)
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Pharma Presentations (listed in alphabetical order)
    Boehringer Ingelheim Licensing

    Boehringer Ingelheim Licensing
    Monday, 13:30–13:45
    Level 0, Stolz 1

    Speaker:
    • Johannes F. Zanzinger – Global Head, CardioMetabolic Business Development and Licensing, Boehringer Ingelheim
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Bayer HealthCare

    Bayer HealthCare
    Monday, 13:45–14:00
    Level 0, Stolz 1

    Speaker:
    • Nigel Sheail – Head, Business Development and Licensing, Bayer HealthCare
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    14:00–14:15
    Roche

    Roche
    Monday, 14:00–14:15
    Level 0, Stolz 1

    Speaker:
    • Alex White – Global Head of Infectious Diseases/Inflammation/Specialty Care/Ophthalmology Partnering, Roche
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    14:15–14:30
    Genentech

    Genentech
    Monday, 14:15–14:30
    Level 0, Stolz 1

    Speaker:
    • Kevin Sin – Director, Head, Oncology, Genentech Partnering
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Janssen Pharmaceutical Companies of Johnson & Johnson

    Janssen Pharmaceutical Companies of Johnson & Johnson
    Monday, 14:30–14:45
    Level 0, Stolz 1

    Speakers:
    • Dr. Günter Huhle – VP NBD and Mature Brands, Janssen Europe, Middle East & Africa
    • Johan Verbeeck – Senior Director Alliance Management, Johnson & Johnson Innovation Center, London
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Takeda Pharmaceutical Company Ltd.

    Takeda Pharmaceutical Company Ltd.
    Monday, 14:45–15:00
    Level 0, Stolz 1

    Speaker:
    • Natalie Mirutenko – Director, Search and Evaluation, Takeda Pharmaceutical Company Ltd.
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    15:00–15:15
    Novo Nordisk

    Novo Nordisk
    Monday, 15:00–15:15
    Level 0, Stolz 1

    Speaker:
    • Tomas Landh – Director, Strategy and Innovation Sourcing, Diabetes Research Unit, Novo Nordisk
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Daiichi Sankyo Co., Ltd.

    Daiichi Sankyo Co., Ltd.
    Monday, 15:15–15:30
    Level 0, Stolz 1

    Speaker:
    • Olaf Koenig – VP, Business Development and New Product Planning Europe, Daiichi Sankyo Europe GmbH
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    15:30–15:45
    Sanofi

    Sanofi
    Monday, 15:30–15:45
    Level 0, Stolz 1

    Speaker:
    • Patrick Tricoli – Global R&D, External Innovation, Scouting and Partnering International, Sanofi
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Shire Pharmaceuticals

    Shire Pharmaceuticals
    Monday, 15:45–16:00
    Level 0, Stolz 1

    Speaker:
    • Charlie Alexander – Senior Director, Business Development, Shire Pharmaceuticals
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Eli Lilly and Company

    Eli Lilly and Company
    Monday, 16:00–16:15
    Level 0, Stolz 1

    Speaker:
    • Alan Lamont – Senior Director, Regional Head ACEJ/Emerging Markets, Global External R&D (G.E.R.D.), Eli Lilly
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Merck Serono, a division of Merck KGaA, Darmstadt

    Merck Serono, a division of Merck KGaA, Darmstadt
    Monday, 16:15–16:30
    Level 0, Stolz 1

    Speaker:
    • Philippe Lopes-Fernandes – Senior VP, Head of Global Licensing and Business Development, Merck Serono
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    16:30–16:45
    MSD

    MSD
    Monday, 16:30–16:45
    Level 0, Stolz 1

    Speaker:
    • Erik Lund – Director, European External Scientific Affairs, MSD
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    16:45–17:00
    Amgen

    Amgen
    Monday, 16:45–17:00
    Level 0, Stolz 1

    Speaker:
    • John O'Connor – Executive Director Licensing, Amgen
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Bristol-Myers Squibb

    Bristol-Myers Squibb
    Monday, 17:00–17:15
    Level 0, Stolz 1

    Speaker:
    • Lubor Gaal – Head of Europe, Search and Evaluation Business Development, Bristol-Myers Squibb
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    17:15–17:30
    AstraZeneca

    AstraZeneca
    Monday, 17:15–17:30
    Level 0, Stolz 1

    Speaker:
    • Maria Dahl – Executive Business Development Director, AstraZeneca
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    17:30–17:45
    Pfizer

    Pfizer
    Monday, 17:30–17:45
    Level 0, Stolz 1

    Speaker:
    • Barbara Dalton – VP, Venture Investments, Pfizer
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Novartis Pharma

    Novartis Pharma
    Monday, 17:45–18:00
    Level 0, Stolz 1

    Speaker:
    • Begoña Carreño – Global BD&L, Head Search and Evaluation Primary Care, Novartis Pharma
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    18:00–18:15
    AbbVie

    AbbVie
    Monday, 18:00–18:15
    Level 0, Stolz 1

    Speaker:
    • John Poulos – VP, Licensing and Acquisitions, AbbVie
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    Alexion Pharmaceuticals

    Alexion Pharmaceuticals
    Monday, 18:15–18:30
    Level 0, Stolz 1

    Speaker:
    • Jeremy P. Springhorn – VP, Corporate Development, Alexion Pharmaceuticals
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    13:30–18:30
    One-to-one Meetings ►
    18:00–18:45
    Level 0, Exhibit Hall
    Exhibit Hall Hospitality Reception

    Join us at booth #56 and learn how the industry's largest network of life science professionals can increase your business opportunities.

    Hosted by:

    partnering360 partnering360
    19:00–22:30
    Evening Networking Reception with Buffet-style Dinner
    Vienna City Hall

    Vienna City Hall
    Friedrich-Schmidt-Platz 1
    Entrance: Felderstrasse 1, Feststiege 2
    1010 Vienna | (map)

    The City Hall is one of the most splendid among the numerous monumental buildings in Vienna. Designed by Friedrich Schmidt (1825-1891) in the Gothic style, it was built between 1872 and 1883. Today the City Hall is the head office of Vienna's municipal administration.

    18:45–19:15 Shuttle buses depart from the congress center to the evening event.
    21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

    Venue made available by:

    City of Vienna City of Vienna

    Cocktail lounge (20:30–22:30) sponsored by:

    Boehringer Ingelheim Licensing Boehringer Ingelheim Licensing

    Tuesday, November 5, 2013
    07:45
    Level 0, Foyer A
    07:45
    Level 0, Hall A
    Exhibition opens and Continental Breakfast
    09:50–11:40
    Level 1, Schubert 5
    Academic Innovators™ Showcase

    Join us for the Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.

    CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences
    Cincinnati Children's Hospital Medical Center
    Fondazione Istituto Italiano di Tecnologia
    Fundación MEDINA
    Johns Hopkins University
    KULeuven - LRD - CD3
    McGill University
    Medical University of Vienna
    PROvendis GmbH
    The Institute of Cancer Research
    University of Vienna
    08:30–18:00
    Company Presentations ►
    08:00–18:30
    One-to-one Meetings ►
    12:00–13:00
    Keynote Plenary Discussion
    A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2013

    Tuesday, 12:00–13:00
    Level 0, Stolz 1

    Moderators:
    Evonne Sepsis – Founder and Managing Director, ESC Advisors
    David Stubbs – Founding Partner and Managing Director, Inverness Advisors

    Panelists:
    • Marc Dunoyer – CFO, AstraZeneca
    • Lubor Gaal – Head of Europe, Search and Evaluation, Business Development, Bristol-Myers Squibb
    • Jordi Sabé – Director Corporate Development, Licensing and M&A, Almirall
    • James Sabry – Senior VP and Global Head of Genentech Partnering, Genentech
    BIO-Europe® 2013
    Share this:Email this pageShare this on LinkedInShare this on Twitter
    13:00–14:00
    Level 0, Exhibit Hall, Foyer Strauss
    Level 1, Restaurants
    Luncheon
    17:45–18:45
    Level 0, Exhibit Hall
    Exhibit Hall Hospitality Receptions

    Hosted by:

    Life Science Nord Life Science Nord LISAvienna LISAvienna Lonza Lonza
    19:00–22:30
    Evening Networking Reception with Buffet-style Dinner
    METAStadt (METAHall)

    METAStadt (METAHall)
    Dr. Otto Neurath Gasse 3
    1220 Vienna | (map)

    Composed of brick buildings more than 100 years old, METAStadt was originally a factory complex for production of steam turbines, locomotive parts and electrical machines. In recent years it has been beautifully restored to unite history and modern design.

    Sponsored by:

    Bayer HealthCare

    18:45–19:15 Shuttle buses depart from the congress center to the evening event.
    21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

    Wednesday , November 6, 2013
    07:45
    Level 0, Foyer A
    07:45
    Level 0, Hall A
    Exhibition opens and Continental Breakfast
    9:00–13:00 Company Presentations ► 8:00–17:00
    One-to-one Meetings ►
    13:00–14:00
    Level 0, Exhibit Hall, Foyer Strauss
    Level 1, Restaurants
    Luncheon
    16:30
    Level 0, Exhibit Hall
    Closing Reception
    Sponsored by:
    Hessen-BiotechHessen-Biotech Hessen Trade and InvestHessen Trade and Invest
    Arrow Up


    © 2009–2014 EBD GmbH
    BIO-Europe EBD Group BIO